# Inhaled Tacrolimus, Add-on to Inhaled Corticosteroids & Long Acting B2 Agonists in Moderate to Severe Persistent Asthma

> **NCT00189722** · PHASE2 · COMPLETED · sponsor: **Astellas Pharma Inc** · enrollment: 160 (actual)

## Conditions studied

- Asthma, Bronchial
- Bronchial Asthma

## Interventions

- **DRUG:** Tacrolimus

## Key facts

- **NCT ID:** NCT00189722
- **Lead sponsor:** Astellas Pharma Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** 2005-07
- **Final completion:** 2005-07
- **Target enrollment:** 160 (ACTUAL)
- **Last updated:** 2008-04-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00189722

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00189722, "Inhaled Tacrolimus, Add-on to Inhaled Corticosteroids & Long Acting B2 Agonists in Moderate to Severe Persistent Asthma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00189722. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*